Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pentostatin · 1 trial · 1 indication
infection=febrile events requiring treatment
| Arm | Type | Description |
|---|---|---|
| Fludarabine, Cyclophosphamide, and Rituximab | ACTIVE_COMPARATOR | Fludarabine, Cyclophosphamide, and Rituximab (dosage based on day in cycle) |
| Pentostatin, Cyclophosphamide, and Rituximab | EXPERIMENTAL | Pentostatin, Cyclophosphamide, and Rituximab (dosage depends on day in cycle) |
| Name | Type | Description |
|---|---|---|
| Fludarabine | DRUG | - |
| Cyclophosphamide | DRUG | - |
| Rituximab | DRUG | - |
| Pentostatin | DRUG | - |
INCLUSION CRITERIA: Patients will be eligible for inclusion in this study if they meet all of the following criteria: * Progressive, histologically proven B-cell CLL. * Stage II, III, or IV B-cell CLL, as defined by Appendix III. Note: The pathology or flow cytometry (of peripheral blood or a bon...
Pentostatin is a small molecule being studied for the treatment of B-Cell Chronic Lymphocytic Leukemia. It is administered in combination with cyclophosphamide and rituximab, and is being evaluated against a regimen of fludarabine, cyclophosphamide, and rituximab in patients with previously untreated or treated disease.
Pentostatin is being developed by McKesson Corporation, which trades under the ticker symbol MCK. The company is conducting clinical research on this drug for B-Cell Chronic Lymphocytic Leukemia.
Pentostatin is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 3 trial has been completed, evaluating its efficacy and safety in patients with B-Cell Chronic Lymphocytic Leukemia.
Pentostatin has one completed Phase 3 trial, NCT00254163, which enrolled 184 participants in the United States. The trial compared pentostatin, cyclophosphamide, and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with B-Cell Chronic Lymphocytic Leukemia.
Pentostatin is a small molecule that works by inhibiting the enzyme adenosine deaminase, which is essential for the proliferation of lymphocytes. By blocking this enzyme, pentostatin disrupts DNA synthesis and leads to the death of cancerous B-cells, making it effective in treating B-Cell Chronic Lymphocytic Leukemia.
Pentostatin is a distinct drug and is not the same as fludarabine, which is used as a comparator in its clinical trial. While both are used in B-Cell Chronic Lymphocytic Leukemia, they have different mechanisms of action and are not interchangeable.